Replies to post #648048 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The data went to a third-party company and was reviewed by statisticians. Your read of the article is flawed. He may now be the repository of the data for the company at this stage, but he neither was the person doing the statistics nor the person who collected the data during the trial, and I know you know this because it was said by the company numerous times, and discussed here. This is just your latest bit of nonsense.

You’ve been here all these years and I know you’ve discussed this at length:

https://nwbio.com/northwest-biotherapeutics-announces-data-lock-of-phase-iii-trial/

05
OCT
2020
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
FOR IMMEDIATE RELEASE

CONTACTS
Dave Innes
804-513-4758
[e-mail]

Les Goldman
240-234-0059
[e-mail]

BETHESDA, Md., October 5, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.

With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.

The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.

“We are excited to be so close to the finish line now, after such a long road” commented Linda Powers, the Company’s CEO. “We are hopeful that DCVax®-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer.”

“We are grateful to the independent service firms and the clinical trial sites who have worked so hard to complete the data collection and confirmation during many months of COVID restrictions and challenges,” Ms. Powers continued. “We are also very grateful to our shareholders for their patience and support, which has made all this possible.”